12 January 2022 - Mitsubishi Tanabe Pharma America today announced the U.S. FDA has accepted the new drug application for an investigational oral formulation of edaravone (MT-1186) for the treatment of amyotrophic lateral sclerosis.
The FDA has accepted the application for priority review with a Prescription Drug User Fee Act action date of 12 May 2022.